Reversible and irreversible cardiac dysfunction associated with trastuzumab in breast cancer

Breast Cancer Research and Treatment

Volumn 74, Issue 2, 2002, Pages 131-134

  Tham, Yee Lu ^a   Verani, Mario S ^a   Chang, Jenny ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Cardiomyopathy; Herceptin ; Trastuzumab

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BREAST CANCER; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; GENE OVEREXPRESSION; HEART DISEASE; HUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTO ONCOGENE; BREAST TUMOR; CARDIOMYOPATHY; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CASE REPORT; FEMALE; HUMAN; MIDDLE AGE; MYOCARDIAL DISEASES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; CARDIOMYOPATHIES; HUMANS; MIDDLE AGED;

EID: 0035990742     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016140729725     Document Type: Article

References (7)

1. Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER2
2. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
3. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
4. Clinical significance of Her-2/neu oncogene amplification in primary breast cancer
5. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
6. Cardiotoxicity in patients receiving trastuzumab (Herceptin): Primary toxicity, synergistic or sequential stress, or surveillance artifact?
7. Characterization of cardiac dysfunction in the Herceptin clinical trials